Lau, Sai Ping http://orcid.org/0000-0002-6876-220X
van Montfoort, Nadine http://orcid.org/0000-0002-7906-7202
Kinderman, Priscilla
Lukkes, Melanie
Klaase, Larissa
van Nimwegen, Menno
van Gulijk, Mandy
Dumas, Jasper
Mustafa, Dana A M
Lievense, Sanne L A
Groeneveldt, Christianne http://orcid.org/0000-0003-1742-1517
Stadhouders, Ralph
Li, Yunlei
Stubbs, Andrew http://orcid.org/0000-0001-9817-9982
Marijt, Koen A
Vroman, Heleen http://orcid.org/0000-0002-4392-935X
van der Burg, Sjoerd H
Aerts, Joachim
van Hall, Thorbald http://orcid.org/0000-0002-9115-558X
Dammeijer, Floris
van Eijck, Casper H J
Clinical trials referenced in this document:
Documents that mention this clinical trial
Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer
https://doi.org/10.1136/jitc-2020-001100
New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)
https://doi.org/10.1136/esmoopen-2019-000510
Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC).
https://doi.org/10.1200/jco.2023.41.4_suppl.757
T-cell agonists in cancer immunotherapy
https://doi.org/10.1136/jitc-2020-000966
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
https://doi.org/10.1136/jitc-2020-000772
Documents that mention this clinical trial
New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)
https://doi.org/10.1136/esmoopen-2019-000510
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
https://doi.org/10.1136/jitc-2020-000772
Documents that mention this clinical trial
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
https://doi.org/10.1136/jitc-2019-000404
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
596 Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab
https://doi.org/10.1136/jitc-2022-sitc2022.0596
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
https://doi.org/10.1136/jitc-2020-000772
Funding for this research was provided by:
Survival with Pancreatic Cancer Foundation (OVIT 17-04, OVIT-17-06)